ORPHA:91500
Tubulointerstitial nephritis and uveitis syndrome
Also known as: Dobrin syndrome · TINU syndrome
Publications
778
90th percentile
Trials
0
Interventional, condition-specific
Researchers
1,168
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare renal tubular disease characterized by early-onset tubulointerstitial nephritis associated with anterior uveitis.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011885
- MeSH:C536922
- OMIM:607665
- UMLS:C1843273
- NCIT:C123021
Additional Mondo synonyms (2)
Tubulointerstitial nephritis and uveitis · acute tubulointerstitial nephritis and uveitis syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
778 matched papers (488 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
778
778 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
778 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
488 in the last 10 years · high confidence · 90th percentile (publications denominator)
Phrase hits: 778 · MeSH hits: 12
Who's working on it?
1,168
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Carreño E5 papers · 2025
Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.
Papers in Europe PMC - 02Yang L5 papers · 2023
Renal Division, Department of Medicine, Peking University First Hospital, Beijing, P.R. China.
Papers in Europe PMC - 03de Boer JH4 papers · 2026
Department of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands.
Papers in Europe PMC - 04
- 05Jahnukainen T4 papers · 2021
Department of Pediatric Nephrology and Transplantation, Children's Hospital, Helsinki University Hospital and Helsinki University, Stenbäckinkatu 11, Box 281, 00029, Helsinki, Finland.
Papers in Europe PMC - 06Davidson SL3 papers · 2025
Perelman School of Medicine at the University of Pennsylvania and Children's Hospital of Philadelphia.
Papers in Europe PMC - 07de-la-Torre A3 papers · 2025
a Uveitis Service, Fundación Oftalmológica Nacional, Rosario University , Bogotá , Colombia and.
Papers in Europe PMC - 08Dohi K3 papers · 2026
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Papers in Europe PMC - 09Fonollosa A3 papers · 2025
Department of Ophthalmology, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Cruces Plaza, 48903, Barakaldo, Bizkaia, Spain.
Papers in Europe PMC - 10Ishida S3 papers · 2026
Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N-15, W-7, Kita-Ku, Sapporo, 060-8638, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Tubulointerstitial nephritis and uveitis syndrome" OR "Dobrin syndrome" OR "TINU syndrome" OR "Tubulointerstitial nephritis and uveitis" OR "acute tubulointerstitial nephritis and uveitis syndrome"
MeSH descriptor terms unioned into the query: Tubulointerstitial nephritis and uveitis
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Tubulointerstitial nephritis and uveitis syndrome" OR "Dobrin syndrome" OR "TINU syndrome" OR "Tubulointerstitial nephritis and uveitis" OR "acute tubulointerstitial nephritis and uveitis syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T04:04:54.225Z